Poland· PL-100433233
Akynzeo
A palonosetron, kombinationen product containing netupitantum + palonosetroni hydrochloridum, registered in Poland by Helsinn Birex Pharmaceuticals Ltd.. The same ATC class is registered in 11 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Palonosetron, kombinationen is registered in 11 of 19 countries.
Countries holding a registration under ATC A04AA55 (palonosetron, kombinationen), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 7 of them publish a price we can compare per daily dose
Palonosetron, kombinationen · ATC A04AA55
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
Price per daily dose
What a daily dose of palonosetron, kombinationen costs, country by country.
Normalised to the WHO defined daily dose (0.5 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Palonosetron, kombinationen · price per daily dose (0.5 mg)
USD · FX 28 Sept 2026
- CH Switzerland$0.20
The record
At a glance
URPL (Poland)- Active substance
- Netupitantum + Palonosetroni hydrochloridum
- Manufacturer
- Helsinn Birex Pharmaceuticals Ltd.
- Country
- Poland (PL)
- ATC code
- A04AA55
- ATC class
- Palonosetron, Kombinationen
- Defined daily dose
- 0.5 mg, O
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Palonosetron, kombinationen in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- IcelandAkynzeoHelsinn Birex Pharmaceuticals Ltd.*
- CzechiaAKYNZEOHelsinn Birex Pharmaceuticals Ltd., Dublin
- FinlandAkynzeoHelsinn Birex Pharmaceuticals Ltd
- NetherlandsAkynzeo 300 mg/0,5 mg harde capsulesHelsinn Birex Pharmaceuticals Limited
- SpainAKYNZEO 300 MG/0,5 MG CAPSULAS DURASHelsinn Birex Pharmaceuticals Limited
- United StatesAKYNZEOHelsinn Therapeutics (U.S.), Inc.
- SwitzerlandAkynzeo
- FranceAKYNZEO 300 mg/0,5 mg, gélulesHELSINN BIREX PHARMACEUTICALS
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Akynzeo
- Liechtenstein · Akynzeo
- Norway · Akynzeo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/4b246f3c-008c-428f-a24d-6e8bce9fb2a4 GET /v1/drugs/4b246f3c-008c-428f-a24d-6e8bce9fb2a4?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Proszek do sporządzania koncentratu roztworu do infuzji",
"source": "urpl",
"strength": "235 mg + 0,25 mg",
"packaging": "Rp ¦ EU/1/15/1001/003 ¦ 135745\n1 fiol. 50 ml\nRp ¦ EU/1/15/1001/004 ¦ 143843\n1 fiol. 20 ml",
"substance": "Netupitantum 235 mg + Palonosetroni hydrochloridum 0.25 mg",
"common_name": "Netupitantum + Palonosetroni hydrochloridum",
"pl_product_id": "100433233",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about palonosetron, kombinationen.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.